Biotech firm’s business model proves a hit with investors

Excerpt: [With] Viva’s valuation highly dependent on fair value gains from its portfolio companies, we believe Viva can just about justify the low-end of IPO price range,” wrote Smartkarma IPO analyst Arun George late last month.Viva, a 11-year-old R&D …

South China Morning Post • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now